Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 12 2022
03 12 2022
Historique:
received:
02
09
2022
accepted:
16
11
2022
entrez:
3
12
2022
pubmed:
4
12
2022
medline:
7
12
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic. New technologies have been utilized to develop several types of vaccines to prevent the spread of SARS-CoV-2 infection, including mRNA vaccines. Our group previously developed an effective DNA-based vaccine. However, emerging SARS-CoV-2 variants of concern (VOCs), such as the delta variant, have escaped mutations against vaccine-induced neutralizing antibodies. This suggests that modified vaccines accommodating VOCs need to be developed promptly. Here, we first modified the current DNA vaccine to enhance antigenicity. Compared with the parental DNA vaccine, the modified version (GP∆-DNA vaccine) induced rapid antibody production. Next, we updated the GP∆-DNA vaccine to spike glycoprotein of the delta variant (GP∆-delta DNA vaccine) and compared the efficacy of different injection routes, namely intramuscular injection using a needle and syringe and intradermal injection using a pyro-drive jet injector (PJI). We found that the levels of neutralizing antibodies induced by the intradermal PJI injection were higher than intramuscular injection. Furthermore, the PJI-injected GP∆-delta DNA vaccine effectively protected human angiotensin-converting enzyme 2 (hACE2) knock-in mice from delta-variant infection. These results indicate that the improved DNA vaccine was effective against emerging VOCs and was a potential DNA vaccine platform for future VOCs or global pandemics.
Identifiants
pubmed: 36463322
doi: 10.1038/s41598-022-24519-5
pii: 10.1038/s41598-022-24519-5
pmc: PMC9719526
doi:
Substances chimiques
Vaccines, DNA
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20923Informations de copyright
© 2022. The Author(s).
Références
Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 (2021).
pubmed: 33024307
doi: 10.1038/s41579-020-00459-7
Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
pubmed: 32015508
pmcid: 7094943
doi: 10.1038/s41586-020-2008-3
Le Thanh, T. et al. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 19, 305–306 (2020).
doi: 10.1038/d41573-020-00073-5
Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626–636 (2021).
pubmed: 34373623
pmcid: 8351583
doi: 10.1038/s41577-021-00592-1
van Riel, D. & de Wit, E. Next-generation vaccine platforms for COVID-19. Nat. Mater. 19, 810–812 (2020).
pubmed: 32704139
doi: 10.1038/s41563-020-0746-0
Callaway, E. The race for coronavirus vaccines: A graphical guide. Nature 580, 576–577 (2020).
pubmed: 32346146
doi: 10.1038/d41586-020-01221-y
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
pubmed: 33378609
doi: 10.1056/NEJMoa2035389
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
pubmed: 33301246
doi: 10.1056/NEJMoa2034577
Uddin, M. N. & Roni, M. A. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines 9, 1–10 (2021).
doi: 10.3390/vaccines9091033
Kis, Z. Stability modelling of mRNA vaccine quality based on temperature monitoring throughout the distribution chain. Pharmaceutics. 14, 1–10 (2022).
doi: 10.3390/pharmaceutics14020430
AboulFotouh, K., Cui, Z. & Williams, R. O. 3rd. Next-generation COVID-19 vaccines should take efficiency of distribution into consideration. AAPS Pharm. Sci. Tech. 22, 126 (2021).
doi: 10.1208/s12249-021-01974-3
Kutzler, M. A. & Weiner, D. B. DNA vaccines: Ready for prime time?. Nat. Rev. Genet. 9, 776–788 (2008).
pubmed: 18781156
pmcid: 4317294
doi: 10.1038/nrg2432
Hayashi, H. et al. Preclinical study of a DNA vaccine targeting SARS-CoV-2. Curr. Res. Transl. Med. 70, 103348 (2022).
pubmed: 35489099
pmcid: 9020527
doi: 10.1016/j.retram.2022.103348
Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21, 73–82 (2021).
pubmed: 33340022
doi: 10.1038/s41577-020-00480-0
Andreano, E. et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc. Natl. Acad. Sci. USA. 118, 36 (2021).
Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372–2383 (2021).
pubmed: 33743213
pmcid: 7953441
doi: 10.1016/j.cell.2021.03.013
Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384–2393 (2021).
pubmed: 33794143
pmcid: 7980144
doi: 10.1016/j.cell.2021.03.036
Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284–1294 (2020).
pubmed: 32730807
pmcid: 7366990
doi: 10.1016/j.cell.2020.07.012
Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021).
pubmed: 33690265
doi: 10.1038/s41586-021-03402-9
Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27, 622–625 (2021).
pubmed: 33654292
doi: 10.1038/s41591-021-01285-x
Davis, C. et al. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog. 17, e1010022 (2021).
pubmed: 34855916
pmcid: 8639073
doi: 10.1371/journal.ppat.1010022
Deng, X. et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184, 3426–3437 (2021).
pubmed: 33991487
pmcid: 8057738
doi: 10.1016/j.cell.2021.04.025
Motozono, C. et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe. 29, 1124–1136 (2021).
Saito, A. et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602, 300–306 (2022).
pubmed: 34823256
doi: 10.1038/s41586-021-04266-9
Chang, C. et al. Stable immune response induced by intradermal DNA vaccination by a novel needleless pyro-drive jet injector. AAPS Pharm. Sci. Tech. 21, 19 (2019).
doi: 10.1208/s12249-019-1564-z
Miyazaki, H., Atobe, S., Suzuki, T., Iga, H. & Terai, K. Development of pyro-drive jet injector with controllable jet pressure. J. Pharm. Sci. 108, 2415–2420 (2019).
pubmed: 30849461
doi: 10.1016/j.xphs.2019.02.021
Nishikawa, T. et al. Anti-CoVid19 plasmid DNA vaccine induces a potent immune response in rodents by Pyro-drive Jet Injector intradermal inoculation. BioRxiv (2021).
Dey, A. et al. Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models. Vaccine. 39, 4108–4116 (2021).
pubmed: 34120764
pmcid: 8166516
doi: 10.1016/j.vaccine.2021.05.098
Khobragade, A. et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): The interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet 399, 1313–1321 (2022).
pubmed: 35367003
pmcid: 8970574
doi: 10.1016/S0140-6736(22)00151-9
Momin, T. et al. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClin. Med. 38, 101020 (2021).
Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).
pubmed: 32433465
pmcid: 7239918
doi: 10.1038/s41467-020-16505-0
Tebas, P. et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClin. Med. 31, 100689 (2021).
de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: Recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016).
pubmed: 27344959
pmcid: 7097822
doi: 10.1038/nrmicro.2016.81
Li, Y. D. et al. Coronavirus vaccine development: From SARS and MERS to COVID-19. J. Biomed. Sci. 27, 104 (2020).
pubmed: 33341119
pmcid: 7749790
doi: 10.1186/s12929-020-00695-2
Zhou, H. et al. A review of SARS-CoV2: Compared with SARS-CoV and MERS-CoV. Front. Med. 8, 628370 (2021).
doi: 10.3389/fmed.2021.628370
Tai, W., Zhang, X., Yang, Y., Zhu, J. & Du, L. Advances in mRNA and other vaccines against MERS-CoV. Transl. Res. 242, 20–37 (2022).
pubmed: 34801748
doi: 10.1016/j.trsl.2021.11.007
Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. USA. 117, 11727–11734 (2020).
pubmed: 32376634
pmcid: 7260975
doi: 10.1073/pnas.2003138117
Hu, J. et al. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis. 7, 551–557 (2020).
pubmed: 32837985
pmcid: 7366953
doi: 10.1016/j.gendis.2020.07.006
Kirchdoerfer, R. N. et al. Pre-fusion structure of a human coronavirus spike protein. Nature 531, 118–121 (2016).
pubmed: 26935699
pmcid: 4860016
doi: 10.1038/nature17200
Kirchdoerfer, R. N. et al. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci. Rep. 8, 15701 (2018).
pubmed: 30356097
pmcid: 6200764
doi: 10.1038/s41598-018-34171-7
Lontok, E., Corse, E. & Machamer, C. E. Intracellular targeting signals contribute to localization of coronavirus spike proteins near the virus assembly site. J. Virol. 78, 5913–5922 (2004).
pubmed: 15140989
pmcid: 415842
doi: 10.1128/JVI.78.11.5913-5922.2004
Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. USA. 114, E7348–E7357 (2017).
pubmed: 28807998
pmcid: 5584442
doi: 10.1073/pnas.1707304114
Wang, X. et al. Deletion of ER-retention motif on SARS-CoV-2 spike protein reduces cell hybrid during cell-cell fusion. Cell Biosci. 11, 114 (2021).
pubmed: 34162440
pmcid: 8220125
doi: 10.1186/s13578-021-00626-0
Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464–1468 (2020).
pubmed: 33184236
pmcid: 7775736
doi: 10.1126/science.abe8499
Korber, B. et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812–827 (2020).
pubmed: 32697968
pmcid: 7332439
doi: 10.1016/j.cell.2020.06.043
Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116–121 (2021).
pubmed: 33106671
doi: 10.1038/s41586-020-2895-3
Callahan, V. et al. The pro-inflammatory chemokines CXCL9 CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner. Viruses. 13, 1062 (2021).
Zheng, J. et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589, 603–607 (2021).
pubmed: 33166988
doi: 10.1038/s41586-020-2943-z
Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327–1335 (2020).
pubmed: 32839612
pmcid: 7578095
doi: 10.1038/s41590-020-0778-2
Huang, Y., Yang, C., Xu, X. F., Xu, W. & Liu, S. W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 41, 1141–1149 (2020).
pubmed: 32747721
pmcid: 7396720
doi: 10.1038/s41401-020-0485-4
Heinz, F. X. & Stiasny, K. Distinguishing features of current COVID-19 vaccines: Knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 6, 104 (2021).
pubmed: 34400651
pmcid: 8368295
doi: 10.1038/s41541-021-00369-6
Teijaro, J. R. & Farber, D. L. COVID-19 vaccines: modes of immune activation and future challenges. Nat. Rev. Immunol. 21, 195–197 (2021).
pubmed: 33674759
pmcid: 7934118
doi: 10.1038/s41577-021-00526-x
Egunsola, O. et al. Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: A systematic review and meta-analysis. JAMA Netw. Open. 4, e2035693 (2021).
pubmed: 33560425
pmcid: 7873776
doi: 10.1001/jamanetworkopen.2020.35693
Jorritsma, S. H. T., Gowans, E. J., Grubor-Bauk, B. & Wijesundara, D. K. Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines. Vaccine. 34, 5488–5494 (2016).
pubmed: 27742218
doi: 10.1016/j.vaccine.2016.09.062
Peachman, K. K., Rao, M. & Alving, C. R. Immunization with DNA through the skin. Methods 31, 232–242 (2003).
pubmed: 14511956
doi: 10.1016/S1046-2023(03)00137-3
Shafaati, M. et al. A brief review on DNA vaccines in the era of COVID-19. Future Virol. 17(1), 49–66 (2021).
doi: 10.2217/fvl-2021-0170
Torres, C. A., Iwasaki, A., Barber, B. H. & Robinson, H. L. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol. 158, 4529–4532 (1997).
pubmed: 9144463
Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa. Nature 603, 679–686 (2022).
pubmed: 35042229
pmcid: 8942855
doi: 10.1038/s41586-022-04411-y
Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2022).
pubmed: 35016196
doi: 10.1038/s41586-021-04387-1
Hachmann, N. P. et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.212.1, BA.4, and BA.5. N. Engl. J. Med. 387, 86–88 (2022).
pubmed: 35731894
doi: 10.1056/NEJMc2206576
Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553–556 (2022).
pubmed: 35240676
pmcid: 9021018
doi: 10.1038/s41586-022-04594-4
Yu, J. et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N. Engl. J. Med. 386, 1579–1580 (2022).
pubmed: 35294809
doi: 10.1056/NEJMc2201849
Matsuura, Y. et al. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 286, 263–275 (2001).
pubmed: 11485395
doi: 10.1006/viro.2001.0971
Tani, H. et al. Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J. Virol. 81, 8601–8612 (2007).
pubmed: 17553880
pmcid: 1951354
doi: 10.1128/JVI.00608-07
Grisanti, L. A. et al. Leukocyte-expressed beta2-adrenergic receptors are essential for survival after acute myocardial injury. Circulation 134, 153–167 (2016).
pubmed: 27364164
pmcid: 5120587
doi: 10.1161/CIRCULATIONAHA.116.022304